Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation

Bone Marrow Transplantation

Volumn 19, Issue 4, 1997, Pages 303-310

  Kiss, J E ^a,b   Rybka, W B ^a   Winkelstein, A ^a   DeMagalhaes Silverman, M ^a   Lister, J ^a   D'Andrea, P ^b   Ball, E D ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b INSTITUTE FOR TRANSFUSION MEDICINE   (United States)

Author keywords

Blood stem cells; Breast cancer; CD34+ cells; Hematopoiesis; Lymphoma

Indexed keywords

CD34 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN;

ADULT; ARTICLE; AUTOTRANSPLANTATION; BREAST CANCER; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GRANULOCYTE; HEMATOPOIESIS; HODGKIN DISEASE; HUMAN; LYMPHOMA; MALE; NEUTROPHIL; NONHODGKIN LYMPHOMA; OVARY CANCER; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; THROMBOCYTE COUNT; TREATMENT FAILURE;

EID: 0031044934     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700671     Document Type: Article

References (36)

1. Goldman J. Peripheral blood stem cells for allografting. Blood 1995; 85: 1413-1415.
2. Siena S, Bregni M, Brando B et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1991; 77: 400-409.
3. Comenzo R, Berkman E. Hematopoietic stem and progenitor cells from blood emerging uses for new components for transfusion. Transfusion 1995; 35: 335-345.
4. Gianni A, Bregni M, Siena S et al. Rapid and complete hematopoietic reconstitution following combined transplantation of autologous blood and bone marrow cells. A changing role for high-dose chemoradiotherapy? Hematol Oncol 1989; 7: 139-148.
5. Sheridan W, Begley CG, Juttner CA et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640-644.
6. Peters W, Rosner G, Ross M et al. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993; 81: 1709-1719.
7. To LB, Roberts MM, Haylock DN et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992; 9: 277-284.
8. Langenmayer I, Weaver C, Buckner CD. Engraftment of patients with lymphoid malignancies transplanted with autologous bone marrow, peripheral blood stem cells or both. Bone Marrow Transplant 1995; 15: 241-246.
9. To LB, Shepperd KM, Haylock DN et al. Single high doses of cyclophosphamide enable the collection of high numbers of hematopoietic stem cells from the peripheral blood. Exp Hematol 1990; 18: 442-447.
10. Socinski M, Cannisora SA, Elias A et al. Granulocyte-macrophage colony stimulating factor expands the circulating hematopoietic progenitor cell compartment in man. Lancet 1988; 1: 1194-1198.
11. Bensinger W, Singer J, Applebaum F et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 1993; 81: 3158-3163.
12. Brugger W, Birken R, Bertz H et al. Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin. Br J Haematol 1993; 84: 402-407.
13. Chao NJ, Schriber JR, Grimes K et al. Granulocyte colony-stimulating factor 'mobilized' peripheral blod progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993; 81: 2031-2035.
14. Elias A, Ayash L. Anderson KC et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 1992; 79: 3036-3044.
15. Sheridan W, Begley CG, To LB et al. Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hemopoiesis after high-dose chemotherapy for lymphoid malignancies. Bone Marrow Transplant 1994; 14: 105-111.
16. Teshima T, Harada M, Takamatsu Y et al. Cytotoxic drug and cytotoxic drug/G-CSF mobilization of peripheral blood stem cells and their use for autografting. Bone Marrow Transplant 1992; 10: 215-220.
17. Haemonetics V50 Plus Operators Manual. Haemonetics Corporation, Braintree, MA, USA, 1991, p 26-1.
18. + hematopoietic stem cells for reconstitution following myeloablative therapy. Cytometry 1994; 16: 74-79.
19. Rybka WB, Geschwend A. Hematopoietic stem cell sources for marrow transplantation and reconstitution. In: Ricordi C (ed). Methods in Cell Transplantation. RG Landes: Austin, Texas, 1995, pp 3-9.
20. Bender J, To LB, Williams S. Schwartzberg LS. Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1992; 1: 329-341.
21. To LB. Mobilizing and collecting blood stem cells. In: Gale R, Juttner C, Henon P (eds). Blood Stem Cell Transplants. Cambridge University Press: Cambridge, UK, 1994, pp 56-74.
22. + cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantation. J Clin Oncol 1995; 13: 1922-32.
23. Zimmerman T, Lee WJ, Bender JG et al. Quantitative CD34 analysis may be used to guide peripheral blood stem cell harvests. Bone Marrow Transplant 1995; 9: 439-444.
24. Hill R, Mazza P, Amos D et al. Engraftment in 86 patients with lymphoid malignancy after autologous marrow transplantation. Bone Marrow Transplant 1989; 4: 69-74.
25. Brandwein JM, Callum J, Sutcliffe SB et al. Analysis of factors affecting hematopoietic recovery after autologous bone marrow transplantation for lymphoma. Bone Marrow Transplant 1990; 6: 291-294.
26. Harada M, Yohshida T, Ishino C et al. Hematologic recovery following autologous and allogeneic bone marrow transplantation. Exp Hematol 1983; 11: 841-848.
27. Kessinger A, Armitage JO, Smith DM et al. High dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood 1989; 74: 1260-1265.
28. + hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intra-venous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989; 74: 1905-1914.
29. Haas R, Ho AD, Bredthauer O et al. Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol 1990; 18: 92-98.
30. Haas R, Mohle R, Fruhauf S et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787-3794.
31. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
32. Kiss JE, Rybka WB, D'Andrea P et al. Analysis of a progenitor cell endpoint to optimize leukapheresis collections for peripheral blood stem cell (PBSC) transplantation. Transfusion 1994; 34: 57a (Abstr.).
33. Nademanee A, Sniecinski I, Schmidt GM et al. High-dose therapy followed by autologous peripheral-blood-stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. J Clin Oncol 1994; 12: 2176-2186.
34. Sutherland JH, Eaves CJ, Lansdorp PM et al. Kinetics of committed and primitive blood progenitor mobilization after chemotherapy and growth factor treatment and their use in auto-transplants. Blood 1994; 83: 3808-3814.
35. Moskowitz C, Stiff P, Gordon M et al. The influence of extensive prior chemotherapy on the mobilization of peripheral blood progenitor cells (PBPC) using stem cell factor (rhSCF) and filgrastim (rmetHuG-CSF) and on hematologic recovery post cyclophosphamide, BCNU, and VP-16 (CBV) in patients with relapsed non-Hodgkin's lymphoma (NHL): an interim analysis. Blood 1994; 84: 107a (Abstr.).
36. Bensinger W, Longin K, Appelbaum F et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87: 825-831.